Combination treatment with arsenic trioxide and sulindac augments their apoptotic potential in lung cancer cells through activation of caspase cascade and mitochondrial dysfunction

International Journal of Oncology

Volumn 28, Issue 6, 2006, Pages 1401-1408

  Kim, Hak Ryul ^a   Kim, Eun Jung ^a   Yang, Sei Hoon ^a   Jeong, Eun Taik ^a   Park, Channy ^a   Kim, Se Jin ^a   Youn, Myung Ja ^a   So, Hong Seob ^a   Park, Raekil ^a  

^a Wonkwang University   (South Korea)

Author keywords

Apoptosis; Arsenic trioxide; Lung cancer cell line; Sulindac

Indexed keywords

ARSENIC TRIOXIDE; GROWTH INHIBITOR; HYDROGEN PEROXIDE; ORGANOARSENIC DERIVATIVE; OXIDE; SULINDAC;

APOPTOSIS; ARTICLE; DRUG EFFECT; FLOW CYTOMETRY; HUMAN; LUNG TUMOR; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

APOPTOSIS; ARSENICALS; CELL LINE, TUMOR; FLOW CYTOMETRY; GROWTH INHIBITORS; HUMANS; HYDROGEN PEROXIDE; LUNG NEOPLASMS; OXIDES; SULINDAC;

EID: 33747092049     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.28.6.1401     Document Type: Article

References (31)

1. Jemal A, Chu KC and Tarone RE: Recent trends in lung cancer mortality in the United States. J Natl Cancer Inst 93: 277-283, 2001.
2. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J and Johnson DH: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346: 92-98, 2002. (Pubitemid 34438899)
3. Giaccone G, Herbst RS, Manegold C, Scagliotti G, Resell R, Miller V, Natale RB, Schiller JH, von Pawel J, Pluzanska A, Gatzemeier U, Grous J, Ochs JS, Averbuch SD, Wolf MK, Rennie P, Fandi A and Johnson DH: Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J Clin Oncol 22: 777-784, 2004. (Pubitemid 41103588)
4. Sandler AB, Johnson DH and Herbst RS: Anti-vascular endothelial growth factor monoclonals in non-small cell lung cancer. Clin Cancer Res 10: 4258-4262, 2004.
5. Antman KH: Introduction: the history of arsenic trioxide in cancer therapy. Oncologist 6: 1-2, 2001.
6. 3) in the treatment of acute promyelocytic leukemia (APL): II, clinical efficacy and pharmacokinetics in relapsed patients. Blood 89: 3354-3360, 1997.
7. Shen ZY, Tan LJ, Cai WJ, Shen J, Chen C, Tang XM and Zheng MH: Arsenic trioxide induces apoptosis of oesophageal carcinoma in vitro. Int J Mol Med 4: 33-37, 1999.
8. Zhang TC, Cao EH, Li JF, Ma W and Qin JF: Induction of apoptosis and inhibition of human gastric cancer MGC-803 cell growth by arsenic trioxide. Eur J Cancer 35: 1258-1263, 1999.
9. Uslu R, Sanli UA, Sezgin C, Karabulut B, Terzioglu E, Omay SB and Goker E: Arsenic trioxide-mediated cytotoxicity and apoptosis in prostate and ovarian carcinoma cell lines. Clin Cancer Res 6: 4957-4964, 2000.
10. Akao Y, Nakagawa Y and Akiyama K: Arsenic trioxide induces apoptosis in neuroblastoma cell lines through the activation of caspase 3 in vitro. FEBS Lett 445: 59-62, 1999.
11. Giardiello FM, Spannhake EW, DuBois RN, Hylind LM, Robinson CR, Hubbard WC, Hamilton SR and Yang VW: Prostaglandin levels in human colorectal mucosa: effects of sulindac in patients with familial adenomatous polyposis. Dig Dis Sci 43: 311-316, 1998. (Pubitemid 28124605)
12. Shiff SJ and Rigas B: Non-steroidal anti-inflammatory drugs and colorectal cancer: evolving concepts of their chemopreventive actions. Gastroenterology 113: 1992-1998, 1997.
13. Shiff SJ, Qiao L, Tsai LL and Rigas B: Sulindac sulfide, an aspirin-like compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colon adenocarcinoma cells. J Clin Invest 96: 491-503, 1995.
14. Chan TA, Morin PJ, Vogelstein B and Kinzler KW: Mechanism underlying non-steroidal antiinflammatory drug-mediated apoptosis. Proc Natl Acad Sci USA 95: 681-686, 1998. (Pubitemid 28083803)
15. Milas L: Cyclooxygenase-2 (COX-2) enzyme inhibitors as potential enhancers of tumor radioresponse. Semin Radiat Oncol 11: 290-299, 2001.
16. Koki AT, Leahy KM and Masferrer JL: Potential utility of COX-2 inhibitors in chemoprevention and chemotherapy. Expert Opin Invest Drugs 8: 1623-1638, 1999.
17. Crissman HA and Steinkamp JA: Cell cycle-related changes in chromatin structure detected by flow cytometry using multiple DNA fluorochromes. Eur J Histochem 37: 129-138, 1993.
18. Kim MS, So HS, Lee KM, Park JS, Lee JH, Moon SK, Ryu DG, Chung SY, Jung BH, Kim YK, Moon G and Park R: Activation of caspase cascades in Korean mistletoe (Viscum album var. coloratum) lectin-II-induced apoptosis of human myeloleukemic U937 cells. Gen Pharmacol 34: 349-355, 2000.
19. 2 release from human granulocytes during phagocytosis. I. Documentation, quantitation, and some regulating factors. J Clin Invest 55: 945-955, 1975.
20. Wolf CM and Eastman A: The temporal relationship between protein phosphatase, mitochondrial cytochrome c release. Exp Cell Res 247: 505-513, 1999.
21. Fokkema E, Groen HJ, Meijer C, Timens W, De Jong S and De Vries EG: The role of apoptosis-related genes in non-small-cell lung cancer. Clin Lung Cancer 4: 174-182, 2002. (Pubitemid 36054497)
22. Torrance CJ, Jackson PE, Montgomery E, Kinzler KW, Vogelstein B, Wissner A, Nunes M, Frost P and Discafani CM: Combinatorial chemoprevention of intestinal neoplasia. Nat Med 6: 1024-1028, 2000.
23. Duffy CP, Elliott CJ, O'Connor RA, Heenan MM, Coyle S, Cleary IM, Kavanagh K, Verhaegen S, O'Loughlin CM, NicAmhlaoibh R and Clynes M: Enhancement of chemotherapeutic drug toxicity to human tumour cells in vitro by a subset of NSAIDs. Eur J Cancer 34: 1250-1259, 1998.
24. Soriano AF, Helfrich B, Chan DC, Heasley LE, Bunn PA Jr and Chou TC: Synergistic effects of new chemopreventive agents and conventional cytotoxic agents against human lung cancer cell lines. Cancer Res 59: 6178-6184, 1999. (Pubitemid 30035640)
25. Jiang TT, Brown SL and Kim JH: Combined effect of arsenic trioxide and sulindac sulfide in A549 human lung cancer cells in vitro. J Exp Clin Cancer Res 23: 259-262, 2004.
26. Bode AM and Dong Z: The paradox of arsenic: molecular mechanisms of cell transformation and chemotherapeutic effects. Crit Rev Oncol Hematol 42: 5-24, 2002. (Pubitemid 34229146)
27. Cai X, Shen YL, Zhu Q, Jia PM, Yu Y, Zhou L, Huang Y, Zhang JW, Xiong SM, Chen SJ, Wang ZY, Chen Z and Chen GQ: Arsenic trioxide-induced apoptosis and differentiation are associated respectively with mitochondrial transmembrane potential collapse and retinoic acid signaling pathways in acute promyelocytic leukemia. Leukemia 14: 262-270, 2000.
28. Woo SH, Park IC, Park MJ, Lee HC, Lee SJ, Chun YJ, Lee SH, Hong SI and Rhee CH: Arsenic trioxide induces apoptosis through a reactive oxygen species-dependent pathway and loss of mitochondrial membrane potential in HeLa cells. Int J Oncol 21: 57-63, 2002.
29. Dai J, Weinberg RS, Waxman S and Jing Y: Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through of the glutathione redox system. Blood 93: 268-277, 1999.
30. Green DR and Reed JC: Mitochondria and apoptosis. Science 281: 1309-1312, 1998.
31. Finucane DM, Bossy-Wetzel E, Waterhouse NJ, Cotter TG and Green DR: Bax induces caspases activation and apoptosis via cytochrome c release from the mitochondria is inhibitable by Bcl-xL. J Biol Chem 274: 2225-2233, 1999.